P2-272: Gemsitabine plus cisplatine therapy in local advanced NSCLC
نویسندگان
چکیده
منابع مشابه
P2: Bumetanide as an Effective Adjunct Therapy in Intractable Epilepsy
لطفاً به چکیده انگلیسی مراجعه شود.
متن کاملAvelumab demonstrates promise in advanced NSCLC
The JAVELIN Solid Tumor clinical trials group recently reported the results of a multi-center open-label phase 1b study (NCT01772004) evaluating avelumab in patients with progressive or platinum-resistant metastatic or recurrent non-small cell lung cancer (NSCLC) [1]. Avelumab, a fully human IgG1 monoclonal antibody (mAb) that binds PD-L1, is currently approved by the U.S. Food and Drug Adminis...
متن کاملCarboplatin/gemcitabine combination in advanced NSCLC.
The treatment of advanced non-small-cell lung cancer (NSCLC) has evolved rapidly over the past few years. Systemic chemotherapy is associated with both quality of life and modest survival benefit for patients with advanced NSCLC. Platinum-based doublet combinations are the "standard of care." The US Food and Drug Administration (FDA) has approved gemcitabine (Gemzar), a pyrimidine analog, to be...
متن کاملABO Blood Groups are Not Associated with Treatment Response and Prognosis in Local Advanced NSCLC
Lung cancer is the leading cause of cancer deaths. Much of the cases are at the advanced stage on diagnosis, so late diagnosis is still an obstacle to improving the outcomes in this malignancy and early stage at diagnosis is an important prognostic factor (Finkelstein et al., 1986). As screening and early diagnosis have been shown to increase survival in some solid tumors as breast, colon and c...
متن کاملIrinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
BACKGROUND From the results of the JCOG9912 and SPIRITS trials, S-1 plus cisplatin (CDDP) therapy (SP) has been recognized as the standard chemotherapy for advanced gastric cancer in Japan. However, in their subsets of patients with the target lesion, irinotecan (CPT-11) plus CDDP therapy (IP) resulted in longer survival than 5-fluorouracil alone while SP exhibited a survival similar to S-1 alo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2007
ISSN: 1556-0864
DOI: 10.1097/01.jto.0000283980.15084.4d